The office, founded to help the company support a growing client need for pricing and market access insights in the region, is headed up by Directors, Guy Bate and Daniel Walsh. Both are experienced pharmaceutical industry consultants with strong networks and in-depth understanding of the healthcare policy environments in the key Asian markets, including China, Japan, Korea and Australia.
Prior to running his own consulting practice in Sydney, Guy was Principal for the Product & Portfolio Strategy practice for IMS Health Consulting in London before relocating to Sydney to head the firm's Australasian practice. During his time at IMS, Guy worked extensively with clients in Asia-Pacific (including Korea, China, Japan, Singapore and Indonesia) to develop IMS's local capabilities and to lead senior client engagements across the region. Before IMS, Guy held positions at Cambridge Pharma Consultancy (now part of IMS Health Consulting), at PA Consulting Group within the Life Sciences & Technology Practice, and as an equities analyst covering the healthcare sector at the investment bank, SG Cowen, in London.
Guy is an Associate Fellow of the Australian Institute of Management. He holds a Wellcome Trust Prize PhD in Molecular Pharmacology and a Bachelor's degree in Physiology.
Daniel worked for several years for Cambridge Pharma Consultancy, advising many of the global top 20 companies on key strategic pricing and market access issues across a broad range of therapeutic areas. Having moved back to Australia Daniel gained further experience as a Senior Consultant with IMS Health's then recent acquisition, the health economics consulting firm M-TAG, developing the strategic pricing and market access capabilities in the Asia-Pacific region. In this role, Daniel led multiple engagements across all of the major countries in the region, developing a strong grasp of the nuances of each country's P&R environment in the process. He left the firm in 2007 to found his own successful consultancy in Sydney.
Daniel holds Bachelor's degrees in Science (biotechnology)
Guy Bate commented: “Asian markets are rapidly evolving and will drive much of the global pharmaceutical growth in coming years. Strategically they are vital to the success of our client companies. However, as in Western countries, healthcare budgets are under significant strain and pricing and market access for new pharmaceuticals will be a challenge; companies will be competing for a piece of the pie. Therefore, an in-depth understanding of the issues that local payers face, and of the way in which pharmaceutical value should be communicated to address these issues, will be vital. RJW is ideally positioned to help ensure our clients are successful.”
Ad Rietveld, founding Director of RJW & Partners Ltd added: “This is a significant step forward for our business. We are delighted that Guy and Dan have joined the organisation as we have a strong history of working together. This decision was motivated partly by the expectations of our clients, but also by our desire to work with Guy and Dan again – you don’t come across this level of talent in most consultancies and it was an opportunity we had to take advantage of.”
RJW & Partners offer a complete suite of services spanning every stage of the product lifecycle including: pricing and market access strategy development, support planning and audit, global and affiliate strategy implementation, the evaluation of new in or out-licensing opportunities and organisational development and improvement. At the core of each assignment is the wish to make a meaningful and commercially tangible contribution to the development of the client’s business, at whatever stage.
